glp 1 agonist fda approved for weight loss Approves Oral Semaglutide as the First Oral GLP-1 Pill? FDA approves Foundayo, an oral

Recently, the introduction of highly effective glucagon-like peptide-1 (GLP-1) receptor agonists has led to increased utilization of obesity medications in this population

A major new study reveals that women who discontinued these medications gained over 3 kg more during pregnancy compared to those who never used them

In these cardiovascular safety trials, in secondary or exploratory analyses, GLP-1 receptor agonists were also shown to reduce macro-albuminuria, an accepted surrogate marker for diabetic kidney disease (DKD), a condition that still represents a major unmet medical need

While GLP-1 RAs induce weight loss in diabetes, their metabolic impact in normoglycaemic PD patients appears limited

Explore the mechanisms, clinical applications, and future opportunities of GLP-1 receptor agonists in drug development and disease management.

* What helps with nausea, constipation, fatigue, and food aversion